Evidence that long-term survival of concordant xenografts is achieved by inhibition of antispecies antibody production.
Antibody and complement have been shown to be of primary importance in the rejection of hamster heart xenografts by rats. Very high anti-hamster antibody titers were detected at the time of rejection of hamster hearts transplanted into untreated or T cell deficient rats. This study demonstrates a method of inhibiting this antibody production by pulse therapy with cyclophosphamide (CyP) and continuous cyclosporine treatment, resulting in a median survival of the hamster heart of greater than 100 days. Controls and CsA-treated rats reject the transplanted hamster heart in a median of 3 days. CyP as a sole therapy resulted in a median survival of 14 days. Prolonged CyP therapy when combined with CsA was associated with increased death among rat recipients due to infection. Antispecies antibody production was suppressed during CyP and CsA therapy and did not recur after cessation of CyP therapy. Cessation of CsA therapy at 60 and 100 days posttransplantation resulted in subsequent rejection of the xenografts (median survival after cessation of therapy of 11 and 19.5 days, respectively) and was associated with production of rat anti-hamster antibodies.
Hasan
R
R
Department of Surgery, Addenbrookes Hospital, Cambridge, United Kingdom.
Van den Bogaerde
J B
JB
Wallwork
J
J
White
D J
DJ
D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D001402:B-Lymphocytes / Q000276:immunology; D006224:Cricetinae; D003520:Cyclophosphamide / Q000494:pharmacology; D006084:Graft Rejection / Q000187:drug effects; D006085:Graft Survival / Q000187:drug effects*; D016027:Heart Transplantation / Q000276:immunology*; D008213:Lymphocyte Activation / Q000187:drug effects; D008647:Mesocricetus; D011292:Premedication; D051381:Rats; D013045:Species Specificity; D014183:Transplantation, Heterologous
D003520:Cyclophosphamide